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The plasma membrane enzyme c-glutamyltransferase (GGT) is regarded as critical for the
maintenance of intracellular levels of glutathione (GSH). GGT expression has been impli-
cated in drug resistance through elevation of intracellular GSH. The dependence of intra-
cellular GSH on GGT expression was not conclusively ascertained. The present study was
designed to investigate the role of GGT and of intracellular GSH levels in modulating prolif-
eration and sensitivity to cisplatin of melanoma cells. GGT transfection resulted in
increased growth, both in vitro and in tumour xenografts. In addition, GGT-transfected cells
exhibited reduced sensitivity to cisplatin associated with lower DNA platination. A
decrease in intracellular GSH levels, rather than an increase, was observed in GGT-transfec-
ted cells; moreover, in cysteine-deficient conditions, the expression of GGT did not provide
transfected cells with the ability of utilising extracellular GSH. In conclusion, these results
indicate that GGTactivity confers a growth advantage unrelated with intracellular glutathi-
one supply, and are consistent with the interpretation that cisplatin resistance is the con-
sequence of modifications of cellular pharmacokinetics as a result of extracellular drug
inactivation by thiol metabolites originated by GGT-mediated GSH cleavage.
 2006 Elsevier Ltd. All rights reserved.1. Introduction
Gamma-glutamyltransferase (GGT) is a cell membrane en-
zyme endowed with the unique capability of initiating the
hydrolysis of extracellular glutathione (GSH, c-Glu-Cys-Gly),
thus potentially providing GGT-positive cells with a secondary
source of cysteine.1 GGT activity is frequently elevated in
human cancers,2 and most cultured cancer cell lines display
elevated GGT activity, which suggests a role for this enzyme
in conferring survival and growth advantages.3 Since intracel-
lular GSH synthesis in vivo is limited by the availability of cys-er Ltd. All rights reserved
fax: +39 2 23902692.
ori.mi.it (F. Zunino).teine,4 it has been speculated that GGT activity would provide
cancer cells with a selective advantage as compared to normal
tissues,5 by enhancing their availability of cysteine. Accord-
ingly, transfection of murine fibroblasts with GGT cDNA
provides them with the ability to use extracellular GSH as a
source of cysteine.6,7 Adequate supplies of cysteine are re-
quired for protein synthesis, as well as synthesis of GSH itself,
which is involved in critical detoxifying and antioxidant de-
fences of the cell. Intracellular GSH is in fact involved in the
resistance of cancer cells to antitumour agents, e.g. plati-
num-based drugs. The increase of GGT expression and of.
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cell resistance to cisplatin8 (CDDP), while the depletion of cel-
lular GSH can sensitise resistant cells to CDDP toxic action.9
Hanigan et al.10 observed that inhibition of GGT enhanced
the antitumour effect of cisplatin in tumour xenografts in vivo.
Nevertheless, direct evidence that GGToverexpression sup-
ports cancer cell growth and drug resistance by increasing
intracellular GSH has never been provided. On the contrary,
(i) several authors reported a decrease of intracellular GSH after
transfection with GGT cDNA;11–13 (ii) no variation, or even a
decrease, in intracellular GSH levels of xenotransplants ob-
tained in nude mice using GGT-transfected tumour cells was
reported,10,14 and (iii) CDDP-resistant melanoma clones
expressing increased GGTactivity exhibited significantly lower
intracellular GSH levels, as compared to GGT-negative clones
derived from the same tumour metastasis.15,16
In contrast, there is evidence that important GGT-medi-
ated reactions occur in the extracellular microenvironment,
where the production of the thiol metabolite cysteinyl-glycine
has been documented to promote prooxidant reactions.17 We
have recently shown that production of cysteinyl-glycine can
represent an extracellular line of defence against CDDP cyto-
toxicity.18,19 In the present study, we show that the transfec-
tion of melanoma cells with GGT cDNA resulted in reduced
sensitivity to cisplatin but did not improve their ability to
maintain their GSH stores when cultured at limiting cysteine
concentrations. The CDDP-resistance of GGT-transfected cells
was consistent with a reduced extent of DNA platination in
GGT-transfected cells, which could not be ascribed to drug
inactivation by intracellular GSH.
2. Materials and methods
2.1. Chemicals
Unless otherwise indicated, all reagents were from Sigma
Chemical Co. (Milan, Italy).
2.2. Cell lines, culture conditions and transfections
Melanoma cell clones, obtained from a subcutaneous human
metastasis (Me 665/2), were kindly provided by Dr. G. Parmiani
(Istituto Nazionale Tumori, Milan, Italy). The c21 clone, pos-
sessing only traces of GGT activity, was used for the present
study. In c21 cells, GGT activity was increased by stable trans-
fection with a vector (pcDNA3, Invitrogen) containing the
full-length cDNA of human GGT.20 A lipid-based transfection
protocol (Lipotaxi mammalian transfection kit, Stratagene)
was used. Of the several subclones thus generated, one pre-
senting high GGT activity (c21/GGT) and one in which no in-
crease of GGT activity was observed (c21/basal) were chosen.
Cells were routinely grown in RPMI 1640 medium, supple-
mented with 5% (v/v) heat-inactivated foetal calf serum,
2 mM L-glutamine (L-Gln) and 0.5 mg/ml G418 (Gibco), under
water-saturated atmosphere with 5% CO2, at 37 C.
2.3. Determination of cell membrane GGT activity
For preparation of cell membrane fractions, confluent cell
monolayers were harvested with hypotonic lysis buffer(10 mM Tris–HCl, pH 7.8). It was ascertained in preliminary
determinations that the levels of GGT activity did not change
after reaching confluence. Harvested cells were disrupted by a
tight-fitting glass–glass Dounce homogeniser (30 strokes).
Crude homogenates were centrifuged at 400g for 10 min,
and then at 100,000g for 60 min, at 4 C. The resulting pellet,
containing cell membranes, was resuspended in hypotonic
buffer. Determination of GGT activity was performed accord-
ing to Huseby and Strømme21 using c-glutamyl-p-nitroanilide
as a substrate and glycyl-glycine as a transpeptidation accep-
tor. The amounts of p-nitroaniline formed were measured by
reading the absorbance at 405 nm and using a molar extinc-
tion coefficient of 9200 L/mol cm. One unit of GGT activity
was defined as 1 lmol of substrate transformed/ml/min.
The results were expressed as mU/mg protein.
2.4. Determination of intracellular GSH and GSSG
Total and oxidised glutathione were assayed by an enzymatic
recycling procedure based on GSH-reductase, adapted to the
microplate reader.22 Acid precipitation of cultured cells or tis-
sue specimens was obtained with suitable volumes of 1% sul-
phosalicylic acid (SSA), and protein precipitates were
resuspended in 0.1 N NaOH. The increase of absorbance at
405 nm was monitored using the microplate reader Labsys-
tem Multiskan Plus MKII (Labsystem, Milan, Italy). GSH con-
tent was estimated by subtracting GSSG from total
glutathione value. The results were expressed as nmol equiv-
alents of GSH/mg protein in the original sample.
2.5. Determination of soluble thiols in cell culture
supernatants
Low molecular weight thiols were determined by HPLC as de-
scribed.23 Aliquots of culture supernatants were diluted twice
in 0.2 M Tris–HCl, pH 8.2, containing 20mM EDTA and 1% SDS,
and reduction of thiolswas performedby adding tris(2-carboxy-
ethyl)-phosphine hydrochloride (5 g/L; Molecular Probes, Invit-
rogen). Thiol derivatisation was then obtained by adding the
fluorogenic reagent 7-fluorobenzofurazan-4-sulphonic acid
ammonium salt (SBD-F, 1 g/L; Fluka). Reverse phase HPLC anal-
ysis was performed with a Beckman System Gold apparatus
equippedwith a RF-551 Shimadzu spectrofluorimetric detector
(ex: 385 nm, em: 515 nm). SBD-F derivatised thiols were sepa-
rated on a Resolve C18 column (Waters), using 5% methanol
in 0.2 M KH2PO4, pH 2.7, as mobile phase (flow rate: 1 ml/min).
2.6. Cell growth at limiting cysteine concentration
Cells were seeded in 24-well plates (10,000 cells/well) in 0.5 ml
of routine medium. After 24 h of growth, the medium was re-
placedwith sulphur-aminoacids free (SAF) RPMI 1640medium,
supplementedwith L-Met, 1% serumand various cysteine con-
centrations. Control incubations were carried out in standard
RPMI 1640 medium, which contains 400 lM cysteine equiva-
lents, 3.25 lMGSH, 100 lM L-Met, and 1% serum. Cultureswere
grown up to 48 h, with one medium change at 24 h. Triplicate
wells were assayed for cell viability daily for each point. The
latter was assayed by means of the WST-1 reagent (Roche)
according to the manufacturer’s protocol. The concentration
Fig. 1 – Growth of c21/basal (A) and c21/GGT (B) cells at
limiting cysteine concentrations. After 24 h of culture,
standard RPMI 1640 medium was replaced with sulphur
aminoacids free (SAF) medium, containing GSH 3 lM and
supplemented with the following cysteine concentrations
(lM): 0 (m); 10 (.); 30 (); 200 (d); 400 (j). Additional
incubations were performed in SAF medium containing
10 lM cysteine and 30 lM GSH together (h). The number of
live cells was estimated by WST-1 assay at the indicated
time points. Results are expressed as the variation of
absorbance during the first 60 min from WST-1 addition.
Data shown are means ± SD of three separate
determinations.
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multilabel counter (Wallac 1420-Victor3, Perkin–Elmer).
2.7. In vivo studies
Experiments were carried out using 9-weeks-old female athy-
mic Swiss nude mice (Charles River, Calco, Italy). Mice were
kept in laminar flow rooms at constant temperature and
humidity with free access to food and water. Experimental
protocols were approved by the Ethics Committee for Animal
Experimentation of the Istituto Nazionale Tumori of Milan
according to institutional guidelines. At day 0, exponentially
growing melanoma cells were subcutaneously (s.c.) injected
on the right flank (9 · 106 cells/mouse) suspended in 0.2 ml
of saline. Mice were inspected daily to establish the take
and the time of tumour appearance. Tumour growth was fol-
lowed by biweekly measurements of tumour diameters with a
Vernier caliper. Tumour volume (TV) was calculated according
to the formula: TV (mm3) = d2 · D/2, where d and D are the
shortest and the longest diameter, respectively. The tumouri-
genicity of the two cell lines was assessed by tumour take, i.e.
the ratio between the number of the growing tumours and
that of the cell-injected mice.
At day 26 after cell injection, mice were sacrificed by cervi-
cal dislocation, tumours were removed and weighed. Tissue
specimens were homogenised in 10 volumes of 5% trichloro-
acetic acid with an Ultraturrax homogeniser (IKA-Labortech-
nik). Homogenates were incubated 30 min on ice and then
centrifuged at 5000g (10 min, 4 C). Supernatants were used
for the determination of intracellular glutathione. Expression
of GGT was verified by histochemistry, in acetone-postfixed
cryostat sections (4 lm thickness), using c-glutamyl-4-meth-
oxy-2-naphthylamide as a substrate and Fast Garnet GBC, as
described.19
2.8. Cell sensitivity to CDDP
Cell sensitivity to CDDP was investigated using two incuba-
tion media: (i) standard RPMI 1640 medium, and (ii) SAF med-
ium to which 10 lM cysteine and 30 lM reduced glutathione
were added. Cells were plated at 4000 cells/well in 96-well
plates. After 24 h, incubationmedia as abovewere substituted
and cell growth was allowed for an additional 24 h. Aliquots
of a CDDP stock solution prepared in PBS were added to the
media for 24 h. Cell viability was then determined immedi-
ately after CDDP exposure by WST-1 assay. The results are ex-
pressed as percentage of control.
2.9. DNA platination
DNA platination was measured as previously described.24
Cells were seeded in T-75 flasks and 48 h later they were ex-
posed to cisplatin for 1 h. DNA was extracted according to
standard procedures. Platinum content was measured by
inductively coupled plasma mass spectroscopy.
2.10. Other determinations
Protein content was determined by the method of Bradford25
using the Bio-Rad protein assay reagent and bovine serumalbumin as standard. Statistical analysis of the data was as-
sessed by ANOVA with Bonferroni test for multiple compari-
son, or Student’s t test (in vivo studies). The results are
reported as means ± SD of three or more experiments.
3. Results
3.1. GGT activity and cell growth at limiting cysteine
concentrations
The c21 melanoma clone used for transfection experiments
possessed a GGT activity of 5.36 ± 3.80 mU/mg protein
(mean ± SD). After transfection of GGT cDNA, two clones
were selected, one presenting no significant variation in
GGT activity (c21/basal cells: 2.35 ± 0.29 mU/mg protein),
and another in which a strong activity was induced (c21/
GGT cells: 138.23 ± 9.11 mU/mg protein). To evaluate the role
of GGT expression in the utilisation of extracellular thiols
and growth rates of c21/basal and c21/GGT cells, these were
studied in SAF medium. In the latter, containing the physi-
ological concentration of GSH (3 lM), increasing concentra-
tions of cysteine were added. Under these experimental
conditions, a significantly higher growth rate was observed
in c21/GGT cells in all conditions tested (Fig. 1), except for
the lowest cysteine concentration (10 lM), at which growth
of c21/GGT cells was inhibited. However, such inhibition
could be reversed by supplementation with 30 lM GSH
(Fig. 1B).
Table 1 – Wet weight and glutathione content of tumours
grown in nude micea
c21/basal c21/GGT
Wet weight (g) 0.45 ± 0.05 0.80 ± 0.02*
GSH (nmol/mg wet wt) 5.38 ± 0.79 4.10 ± 0.46*
a Data obtained at day 26 after cell injection. Data are means ± SD
of 6 separate determinations.
* P < 0.05.
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The ability of transfected cell lines to grow in vivo and to uti-
lise extracellular thiols was further investigated after trans-
plantation in nude mice, i.e. in conditions of physiologically
low cysteine availability. As judged from tumour volume
(Fig. 2) and weight (Table 1), growth of c21/GGT cells in vivo
was higher than that of c21/basal cells. The difference in tu-
mour volume was significant at the end of the experiment
(P < 0.01). Histochemical analysis confirmed that tumours de-
rived from c21/GGT cells possessed high GGT activity, both at
cytoplasmic and cell membrane level (Fig. 3). GSH levels were
significantly lower in tumours originated by c21/GGT cells
(Table 1).
3.3. Cell sensitivity to CDDP
The antiproliferative effects of CDDP were assayed in stan-
dard RPMI 1640 medium as well as, for comparison, in modi-
fied SAF medium containing 10 lM cysteine. SAF medium
also included 30 lM GSH, to verify its possible utilisation by
GGT-expressing cells. The sensitivity of melanoma clones to
CDDP was examined using the WST-1 assay after 24 h drug
exposure. Under such experimental conditions (Fig. 4A and
B), c21/GGT cells were significantly more resistant than c21/
basal cells in both incubation conditions. In SAF-incubated
cells, the difference was more marked, with an IC50 value of
c21/GGT cells approximately five times higher than that of
c21/basal cells (Fig. 4B).Fig. 2 – In vivo growth of human melanoma clones. Tumour
cells (9 · 106) were injected s.c. in nude mice on the right
flank; see Section 2 for further details. Data are means (±SD)
of six tumours. *P < 0.01.3.4. DNA-bound Pt after cisplatin exposure
Since DNA is recognised as the primary cellular target of cis-
platin, we examined DNA-bound platinum in c21/GGT and
c21/basal cells after 1 h drug exposure in standard RPMI 1640
medium. The amount of platination was reduced in c21/GGT
cells, thereby suggesting that the observed decreased sensitiv-
ity of the cellswith higher GGTactivity reflects a reduced inter-
action of the drug with the intracellular target (Fig. 5).
3.5. Dependence of intracellular glutathione levels on extra-
cellular cysteine and GSH levels
When cultured in standard RPMI 1640 medium, c21/GGT cells
exhibited lower intracellular GSH and higher GSSG levels than
c21/basal cells, even though the higher membrane GGT activ-
ity of c21/GGT cells was expected to favour the maintenance
of intracellular GSH levels (Table 2).
Similar results were obtained in SAF-cultured cells. Intra-
cellular GSH concentrations in c21/basal and c21/GGT clones
were independent of GGT expression, and appeared to de-
pend solely on extracellular cysteine. In 10 lM cysteine-con-
taining SAF, supplementation of medium with 30 lM GSH
allowed increased intracellular glutathione in both cell lines
(Fig. 6), again suggesting that GGT activity was not involved
in the modulation of intracellular GSH.
3.6. GGT expression and extracellular low molecular
weight thiols
Low molecular weight thiols were determined in the culture
supernatants of the two transfected clones. As reported in Ta-
ble 3, high extracellular levels of GSH were present in the
supernatant from c21/basal cells, along with very low cys-
teinyl-glycine. The situation was reversed with c21/GGT cells,
exhibiting very low extracellular GSH and high cysteinyl-gly-
cine levels, resulting from GGT-mediated catabolism of GSH.
Extracellular cysteine levels were instead comparable in the
two clones.
4. Discussion
The present study suggests that the relationships of GGTwith
cellular thiol metabolism and functions are more complex
than those currently recognised. Overexpression of GGT pro-
vided human melanoma cells26 with increased growth capa-
bility, both in vitro (Fig. 1) and in vivo (Fig. 2, Table 1).
However, the expression of GGT did not favour the intracellu-
lar supply of GSH; indeed, both xenotransplants and cultured
Fig. 5 – DNA-bound platinum in c21/basal as compared to
c21/GGT cells. Cells were exposed to cisplatin for 1 h.
Platination was measured by inductively coupled plasma
mass spectroscopy. Values shown are means ± SD of three
measurements.
Fig. 4 – Cell sensitivity to CDDP. c21/basal (h) and c21/GGT
(j) cells were seeded and grown for 24 h in standard RPMI
1640 medium, containing 400 lM cysteine and 3.25 lM GSH
(A), or in conditions of limiting cysteine availability
(B; cysteine 10 lM, GSH 30 lM), before treating with the
indicated concentrations of CDDP. Cells were incubated 24 h
with CDDP and the number of live cells was measured
thereafter using WST-1 assay. Results are expressed as % of
untreated controls, and are means ± SD of 12–36
independent replications. *P < 0.001.
Fig. 3 – Histochemical staining for GGT enzyme activity (red) in frozen sections obtained from tumours grown in
immunodeficient nude mice, produced by (A) c21/basal cells and (B) c21/GGT cells. Magnification: 400·. (For interpretation of
the references to colour in this figure legend, the reader is referred to the Web version of this article.)
Table 2 – Intracellular GSH and GSSG levelsa
nmol GSH eq./mg protein c21/basal c21/GGT
Total (GSH + GSSG) 74.74 ± 2.11 60.14 ± 4.75*
GSSG 0.26 ± 0.09 0.43 ± 0.01**
GSH (Total–GSSG) 74.48 ± 2.11 59.71 ± 4.75*
GSH/GSSG ratio 286.46 138.86
a Determinations were performed 72 h after plating cells in stan-
dard conditions. Data are means ± SD of 3 separate
determinations.
* P < 0.01.
** P < 0.05.
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fection (Tables 1 and 2). These findings are in keeping with
previous observations in different cell systems, including
chemically transformed murine epidermal cells and human
prostatic cancer cells.10,14
It has been proposed that the expression of GGT might
provide tumour cells with a selective growth advantage at
limiting cysteine concentrations.5 However, the results re-
ported in the present study indicate that the expression of
GGT is not accompanied by increased intracellular GSH sup-
ply, and therefore this parameter cannot explain the in-
creased proliferation of GGT-transfected cells, both in vitro
and in vivo.
GGT expression also induced CDDP resistance in transfec-
ted cells, which exhibited a higher IC50 than c21/basal
(Fig. 4A and B) and decreased levels of DNA platination
(Fig. 5). The finding cannot however be explained by any
increase of intracellular GSH (Tables 1 and 2); rather, thehigher CDDP resistance of c21/GGT cells is likely due to the
reactivity of cysteinyl-glycine, produced by GGT-mediated
GSH catabolism (Table 3). We have in fact previously shown
that cysteinyl-glycine is considerably more reactive than
GSH in forming complexes with CDDP,18,19 and that GGT-
expressing cells are in this way capable of promoting the
Fig. 6 – Dependence of intracellular glutathione levels of c21/
basal (A) and c21/GGT (B) cells on extracellular cysteine and
GSH. After 24 h of culture, standard RPMI 1640 medium was
replaced with SAF medium, containing 3 lM GSH and
supplemented with the following cysteine concentrations
(lM): 0 (m); 10 (.); 30 (); 200 (d); 400 (j). Additional
incubations were performed in SAF medium containing
10 lM cysteine and 30 lM GSH together (h). Intracellular
concentration of GSH was measured at the indicated time
points and expressed as percentage of time 0. Data shown
are means ± SD of three separate determinations.
Table 3 – Extracellular accumulation of low molecular
weight thiols in the supernatant of melanoma clonesa
lM C21/basal c21/GGT
GSH 4.69 ± 0.48 0.47 ± 0.11*
CysGly 0.15 ± 0.05 6.17 ± 0.19**
Cys 6.15 ± 1.20 7.66 ± 0.60
a Low molecular weight thiols were assayed after 24 h cell culture
in SAFmedium. Data are means ± SD of 3 separate determinations.
* P < 0.01.
** P < 0.001.
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DNA platination suggests a decreased intracellular accumu-
lation of CDDP or a decreased reactivity of CDDP/thiol com-
plexes with intracellular targets. The difference in CDDP
resistance was more evident when cells were treated in
the presence of low cysteine (10 lM) and high GSH (30 lM)
concentrations (Fig. 4B). Under these conditions in fact,
deprivation of thiol precursors for GSH resynthesis only af-
fects the resistance of c21/basal cells, which rely for their
defences solely on intracellular GSH stores. On the contrary,
c21/GGT cells, being able to metabolise exogenous GSH, can
take advantage of the protection provided by the extracellu-
lar cysteinyl-glycine thus formed.
A favouring role of GGT activity in cellular supply of GSH
could not be found even in the presence of limiting cysteine
concentrations (Fig. 6). Under these conditions, the expres-
sion of GGT did not allow the maintenance of intracellular
GSH; the latter instead decreased in time, with comparable
rates in c21/basal and c21/GGT. In both clones, depletion ofintracellular GSH was, however, delayed in the presence of
exogenously added GSH (30 lM). This effect can be explained
as the result of the reducing action of GSH on the extracellular
redox status;27 reducing conditions were shown to favour the
cellular uptake of cysteine/cystine. In different cell types,
membrane transport of cysteine is more efficient than that
of cystine,28,29 and thus extracellular reducing agents like N-
acetylcysteine,29,30 cysteinyl-glycine29 and GSH itself29,31 can
favour the cellular thiol supply by reducing the extracellular
cystine to more rapidly absorbed cysteine. Cystine is present
in standard RPMI 1640 medium, and accumulates extracellu-
larly with both cell lines studied – likely as the result of cellu-
lar secretion and subsequent autoxidation of cysteine (Table
3).16 At least with c21/GGT cells, the reduction of cystine
might in principle be affected by cysteinyl-glycine, which in-
deed accumulates extracellularly as the result of GGTactivity.
However, c21/GGT cells did not transport more cystine than
c21/basal cells (Table 3), likely because the amount of cys-
teinyl-glycine formed (approximately 6 lM, cf. Table 3) is too
low. In fact, higher levels of reducing thiols are needed for
producing significant effects29 (30–60 lM).
Both growth rate and resistance to CDDP appeared to be
independent of GSH as a secondary source of cysteine, thus
indicating that the important effects caused by GGT activity
are unrelated to cellular supply of GSH thiol precursors. Pre-
vious studies carried out in our and other laboratories have
shown that GGT activity can participate in redox processes
taking place in the extracellular microenvironment.32–36 In
fact, cysteinyl-glycine released after GSH hydrolysis was
shown to catalyse the extracellular production of reactive
oxygen species, including hydrogen peroxide.32,33 Through
the action of these reactive compounds, GGT activity can
give rise to cytotoxic injuries.34–36 In contrast, more subtle
and physiological changes have been described, such as
the oxidation/S-thiolation of thiol groups of cellular pro-
teins.16,32,37 Modulating, rather than injuring, effects have
been observed on several redox-sensitive components of sig-
nal transduction chains, such as the transcriptions factors
NF-jB and AP-133,38,39 and protein tyrosine or serine/threo-
nine kinase/phosphatase balance.40 Oxidative changes pro-
duced by GGT activity may activate redox-sensitive and
protective pathways enabling cells to survive under stress
conditions. Moreover, pro-oxidant effects of GGT were also
described for elements involved in the proliferation/apopto-
tic balance, such as poly(ADP-ribose) polymerase activity
and the cell surface receptor TNFR-1.12,41 Altogether, such
modulatory changes might well account for the changes in
cellular growth rates induced after GGT transfection in the
present study, as well as for the previously shown involve-
ment of GGT in mediating GSH-dependent antiproliferative
effects in ovarian carcinoma cells.42
In conclusion, the present findings indicate that GGT
expression in melanoma cells results in growth advantage
in vitro and in vivo, as well as in increased CDDP-resistance.
Neither effect can be attributed to facilitating effects of GGT
on the cellular supply of cysteine or glutathione. Rather,
CDDP resistance is likely the consequence of cellular phar-
macokinetics as a result of extracellular drug inactivation
by thiol metabolites originated from GGT-mediated GSH
cleavage.
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